<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11461067</article-id><article-id pub-id-type="pmc">2364040</article-id><article-id pub-id-type="pii">6691897</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1897</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Riccardi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pugliese</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Danova</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brugnatelli</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grasso</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giordano</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bernardo</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Giardina</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fava</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Montanari</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Pedrotti</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Trotti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Rinaldi</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Poli</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Tinelli</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">11</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Medicina Interna ed Oncologia Medica, <label>11</label>Servizio di Biometria ed Epidemiologia Clinica, Universit&#x000e0; and IRCCS Policlinico S. Matteo, Pavia, 27100</aff><aff id="aff2"><label>2</label>Servizio di Oncologia, Ospedale S. Anna, Como, 22100</aff><aff id="aff3"><label>3</label>Servizio di Oncologia Medica e Riabilitazione, Fondazione Maugeri, Pavia, 27100</aff><aff id="aff4"><label>4</label>Centro Senologico, Ospedale di Circolo, Varese, 21100</aff><aff id="aff5"><label>5</label>Divisione di Medicina II, Ospedale di Legnano, Legnano, 20025</aff><aff id="aff6"><label>6</label>Divisione di Medicina Generale, Ospedale di Lodi, Lodi, 20075</aff><aff id="aff7"><label>7</label>Divisione di Medicina, Ospedale di Sondalo, Sondalo, 23035</aff><aff id="aff8"><label>8</label>Divisione di Medicina Generale II, Ospedale di Busto Arsizio, Busto Arsizio, 21052</aff><aff id="aff9"><label>9</label>Divisione di Medicina I, Ospedale di Magenta, Magenta, 20013</aff><aff id="aff10"><label>10</label>Divisione di Radioterapia, Ospedale di Cremona, Cremona, 26100, Italy</aff><pub-date pub-type="ppub"><month>07</month><year>2001</year></pub-date><volume>85</volume><issue>2</issue><fpage>141</fpage><lpage>146</lpage><history><date date-type="received"><day>18</day><month>01</month><year>2001</year></date><date date-type="rev-recd"><day>17</day><month>04</month><year>2001</year></date><date date-type="accepted"><day>02</day><month>05</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade III&#x02013;IV toxicity was acceptable. Leukopenia occurred in 26&#x00025; of patients, thrombocytopenia in 2&#x00025; and anaemia in 4&#x00025;. One patient had reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9&#x00025; and 4&#x00025; of patients, respectively and one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal (<italic>n</italic>= 1), cardiac toxicity (<italic>n</italic>= 1), early death during FEC chemotherapy (<italic>n</italic>= 1), major protocol violations (<italic>n</italic>= 4), hypersensitivity reaction (<italic>n</italic>= 1) and early death during paclitaxel chemotherapy (<italic>n</italic>= 1). The overall response rate was 65&#x00025; (95&#x00025; CI = 53&#x02013;76), and 7&#x00025; of patients had stable disease. Therapy was defined as having failed in 28&#x00025; of patients because they were not evaluable (13&#x00025;) or had progressive disease (15&#x00025;). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major haematologic toxicity and has a good antitumour effect. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>advanced breast cancer</kwd><kwd>anthracycline-containing regimen</kwd><kwd>paclitaxel</kwd><kwd>sequential chemotherapy</kwd></kwd-group></article-meta></front></article>


